News

While researchers have known that AREDS 2 supplements help slow the progression of AMD from the intermediate stage to the late stage, they wanted to establish whether supplementation could impact t...

Researchers have recently discovered that the enzyme, telomerase, plays a role in abnormal blood vessel formation in lab mice and this discovery may lead to new therapies in treating the wet form ...

EyePoint Pharmaceuticals announced the completion of the Phase 2 trial of their new experimental drug, vorolanib, for the treatment of wet age-related macular degeneration.

The current available therapies available to treat wet AMD involve intravitreal injections delivered every month to the back of the eye. 

The Food and Drug Administraton (FDA) gave approval after two active-controlled, double-masked pivotal trials, which compared EYLEA HD to EYLEA over a 48 week period.

The Food and Drug Administration (FDA) recently announced their approval of Izervay for treatment of geographic atrophy (GA) secondary to age-related macular degeneration.

The new drug is manufactured by 4D Molecular Therapeutics and is a dual-transgene intravitreal gene therapy.

Artificial intelligence may be the key in helping doctors determine which patients with intermediate AMD are at a high risk of the disease progressing to geographic atrophy.

Researchers concluded that anti-VEGF treatments do raise the risk of glaucoma progression.